The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board
View More
25th Annual International Lung Cancer Congress®
July 25-27, 2024
Register Now!
24th Annual International Lung Cancer Congress®
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Polypharmacy and the Pivotal Role of the Payer
June 3rd 2024A SCAN Health Plan "deprescribing" program is working to identify unnecessary prescriptions. In 2023, the program resulted in an estimated $2 million in savings from avoided fractures, falls, visits to the emergency room and other adverse drug events.
FDA Updates for Week of May 27: 2 Approvals including New Biosimilar
June 1st 2024The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi for mantle cell lymphoma. The agency has delay a decision on Dupixent in COPD and has set goal dates for zolbetuximab in gastric cancer and zanidatamab in bile duct cancer.
Strategies to Help Health Plans Prepare for Risk Adjustment, Star Ratings Changes
May 31st 2024One of the changes that CMS has added is a Health Equity Index (HEI) reward to its Stars program. The agency will use HEI data collected this year and next to calculate 2027 Star Ratings, so plans must capture member data on every measure included in the HEI.